Genmab A/S (GMAB.CO)
Genmab A/S reported revenue of 3.7B USD for the year ending 31 December 2025, up 19.2% from 3.1B a year earlier.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in USD.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
2025 · ending 31 December 2025 |
3.7B |
+19.2% |
| Gross Profit |
2025 · ending 31 December 2025 |
3.5B |
+16.9% |
| Operating Income |
2025 · ending 31 December 2025 |
1.1B |
+9.6% |
| Net Income |
2025 · ending 31 December 2025 |
963M |
-15.0% |
| Cost of Revenue |
2025 · ending 31 December 2025 |
238M |
+66.4% |
| Operating Cash Flow |
2025 · ending 31 December 2025 |
1.2B |
+5.3% |
| Free Cash Flow |
2025 · ending 31 December 2025 |
1.1B |
+4.5% |
| Shares Outstanding |
2026 · ending 1 January 2026 |
62.7M |
-3.1% |
| EPS |
2025 · ending 31 December 2025 |
15.37 |
-12.3% |
Revenue and profit by financial year
As filed, in USD. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
3.7B | 1.1B | 963M | 1.1B |
|---|
| 2024 | 2024-12-31 |
3.1B | 972M | 1.1B | 1.1B |
|---|
| 2023 | 2023-12-31 |
2.4B | 772M | 631M | 1B |
|---|
Every period
Revenue Annual
| Period | Ending | Revenue |
|---|
| FY25 | 2025-12-31 | 3.7B |
|---|
| FY24 | 2024-12-31 | 3.1B |
|---|
| FY23 | 2023-12-31 | 2.4B |
|---|
Gross Profit Annual
Revenue minus cost of sales. This filer tags no gross profit of its own..
| Period | Ending | Gross Profit |
|---|
| FY25 | 2025-12-31 | 3.5B |
|---|
| FY24 | 2024-12-31 | 3B |
|---|
| FY23 | 2023-12-31 | 2.4B |
|---|
Operating Income Annual
| Period | Ending | Operating Income |
|---|
| FY25 | 2025-12-31 | 1.1B |
|---|
| FY24 | 2024-12-31 | 972M |
|---|
| FY23 | 2023-12-31 | 772M |
|---|
Net Income Annual
| Period | Ending | Net Income |
|---|
| FY25 | 2025-12-31 | 963M |
|---|
| FY24 | 2024-12-31 | 1.1B |
|---|
| FY23 | 2023-12-31 | 631M |
|---|
Cost of Revenue Annual
| Period | Ending | Cost of Revenue |
|---|
| FY25 | 2025-12-31 | 238M |
|---|
| FY24 | 2024-12-31 | 143M |
|---|
| FY23 | 2023-12-31 | 33M |
|---|
Operating Cash Flow Annual
| Period | Ending | Operating Cash Flow |
|---|
| FY25 | 2025-12-31 | 1.2B |
|---|
| FY24 | 2024-12-31 | 1.1B |
|---|
| FY23 | 2023-12-31 | 1.1B |
|---|
Free Cash Flow Annual
Operating cash flow minus capital expenditure.
| Period | Ending | Free Cash Flow |
|---|
| FY25 | 2025-12-31 | 1.1B |
|---|
| FY24 | 2024-12-31 | 1.1B |
|---|
| FY23 | 2023-12-31 | 1B |
|---|
Shares Outstanding Annual
Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.
| Period | Ending | Shares Outstanding |
|---|
| FY26 | 2026-01-01 | 62.7M |
|---|
| FY25 | 2025-01-01 | 64.6M |
|---|
| FY24 | 2024-01-01 | 65.9M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | 15.37 |
|---|
| FY24 | 2024-12-31 | 17.53 |
|---|
| FY23 | 2023-12-31 | 9.58 |
|---|